Tarra Millender, MD
Ophthalmology · Southern Pines, NCNPI 1033242581
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 251 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 22 manufacturers reported payments, led by Alcon at 26.3% of the total.
Across 251 payments — averaging $20.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$1K
- AbbVie$998
- Bausch & Lomb, A Division Of Bausch Health US, LLC$418
- Ocular Therapeutix, Inc.$389
- Glaukos Corporation$349
- Ivantis, Inc$318
- plus $1K from 16 others
Across 23 payments — averaging $1101.11 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$20K
- Glaukos Corporation$5K
What the payments were for
- Food & beverage$5,220100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 85 | $1,372 |
| AbbVie(2 entities) | 41 | $998 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 20 | $418 |
| Ocular Therapeutix, Inc. | 17 | $389 |
| Glaukos Corporation | 11 | $349 |
| Ivantis, Inc | 14 | $318 |
| Biotissue Holdings Inc. | 18 | $276 |
| Bausch & Lomb Americas Inc. | 8 | $244 |
| Mallinckrodt Hospital Products Inc. | 11 | $192 |
| Thea Pharma Inc. | 1 | $127 |
| Rxsight Inc | 2 | $100 |
| Johnson & Johnson Surgical Vision, Inc. | 3 | $92 |
| Rayner Intraocular Lenses Limited | 6 | $89 |
| Shire North American Group Inc | 3 | $69 |
| Kala Pharmaceuticals, Inc. | 3 | $44 |
| Akorn Operating Company LLC | 2 | $35 |
| Oyster Point Pharma, Inc. | 1 | $26 |
| Amgen | 1 | $20 |
| NEW World Medical,inc. | 1 | $18 |
| Iridex Corporation | 1 | $18 |
| Eyepoint US, Inc. | 1 | $13 |
| GSK | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Hydrus Microstent$375
- XEN GLAUCOMA TREATMENT SYSTEM$265
- IYUZEH$127
- enVista MX60 IOL$117
- MIEBO$113
- XIIDRA$113
- XEN$112
- TOTAL30$100
How this compares
$5,220 in reported general payments places this provider in the 80th percentile of 588 ophthalmology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 88 | $100,873 |
| LumiganBimatoprost | 206 | $97,889 |
| CombiganBrimonidine Tartrate/Timolol | 153 | $62,473 |
| RocklatanNetarsudil Mesylat/Latanoprost | 60 | $32,078 |
| VyzultaLatanoprostene Bunod | 62 | $26,929 |
| Alphagan PBrimonidine Tartrate | 64 | $24,176 |
| Brimonidine Tartrate | 252 | $22,831 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 93 | $20,456 |
| Prednisolone Acetate | 416 | $19,625 |
| ProlensaBromfenac Sodium | 29 | $17,469 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 72 | $13,680 |
| Latanoprost | 777 | $10,853 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 67 | $10,087 |
| Brinzolamide | 40 | $9,156 |
| Lotemax SmLoteprednol Etabonate | 31 | $8,579 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan, Alphagan P | $998 | $285,411511 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Lotemax Sm, Loteprednol Etabonate | $418 | $31,54892 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $244 | $26,92962 claims |
| AlconSimbrinza | $1,372 | $20,45693 claims |
| Thea Pharma Inc.Iyuzeh | $127 | $4,79512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 588 ophthalmology providers in North Carolina.
Other ophthalmology in Southern Pines
- Arghavan AlmonySouthern Pines$87K
- Anna FakadejSouthern Pines$18K
- Winston GarrisSouthern Pines$10K
- Robert SharpeSouthern Pines$8K
- Preeya GuptaRaleigh$1.8M
- Julie WoodwardDurham$1M
- Rajiv ShahWinston Salem$909K
- Lejla VajzovicDurham$681K
- Karl StonecipherGreensboro$653K
- Terry KimDurham$605K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.